In Silico Designing a Candidate Vaccine Against Breast Cancer
In Silico Designing a Candidate Vaccine Against Breast Cancer
复制标题
DOI：
10.1007/s10989-019-09843-1
复制
发表时间：
2020-03-01
影响因子：
2.5
通讯作者：
Nezafat, Navid
中科院分区：
文献类型：
--
作者：
Atapour, Amir;Negahdaripour, Manica;Nezafat, Navid
乳腺癌（BC）是最常见的女性癌症类型，患病率约为25%，尽管在男性中罕见（< 1%）。到目前为止，由于各种原因，BC治疗方法尚未成功。本研究的目的是利用生物信息学工具设计一种针对BC的候选疫苗。本文采用芯片设计了一种含有HER-2/neu蛋白胞外结构域和GP96蛋白（NTGP96） n端序列的融合疫苗候选物。使用不同的生物信息学和免疫信息学软件来研究设计的疫苗的重要特征，包括物理化学性质、二级和三维结构，以及抗原性和过敏原性。结构和免疫学计算结果表明，我们设计的结构具有适当刺激针对BC的细胞和体液免疫反应的潜力。根据所获得的数据，经体内和体外免疫试验证实候选疫苗的有效性后，可以引入BC治疗。
Breast cancer (BC) is the most common type of women's cancer with a prevalence of about 25%, although it is rare in men (< 1%). Until now, BC therapy approaches have not been successful for various reasons. The purpose of this study was to design a candidate vaccine against BC using bioinformatics tools. Herein, in silico design of a fusion vaccine candidate containing extracellular domain of HER-2/neu protein and N-terminal sequence of GP96 protein (NTGP96) were performed. Different bioinformatics and immunoinformatics softwares were used to study the important characteristics of the designed vaccine, including physicochemical properties, secondary, and 3D structures, as well as antigenicity and allergenicity. Structural and immunological computational results indicated the potential of our designed construct for proper stimulation of cellular and humoral immune responses against BC. According to the obtained data, the candidate vaccine could be introduced for BC therapy, after the efficacy of it was confirmed by in vivo and in vitro immunological assays.